BRCA1 and ovarian carcinoma: For BRCA1/BRCA2 mutation-positive platinum-sensitive epithelial ovarian cancer, though poly ADP-ribose polymerase inhibitor has been recommended as the maintenance therapy since 2019, still, several placebo-controlled trials on next-in-class poly ADP-ribose polymerase inhibitor have been initiated subsequently.